Skip to search formSkip to main contentSkip to account menu

nebicapone

Known as: 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Acetophenones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs
Objectives  Patients with Parkinson's disease can benefit from controlled released levodopa dosage forms since there is a clear… 
Review
2010
Review
2010
Toxicology and safety of COMT inhibitors.
2010
2010
Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor
Abstract Objective: To investigate the chronopharmacology of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor… 
2010
2010
Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
OBJECTIVE This study investigated the absorption, distribution, metabolism and excretion (ADME) of nebicapone [BIA 3-202; 1-(3,4… 
2009
2009
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover…
2008
2008
Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
ObjectiveNebicapone is a new catechol-O-methyltransferase inhibitor. In vitro, nebicapone has showed an inhibitory effect upon… 
2008
2008
Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg
AbstractBackground and objectives: Levodopa is the most effective symptomatic treatment for Parkinson’s disease (PD), but its use… 
2007
2007
Membrane‐bound COMT inhibition by Nebicapone
Nebicapone is a new nitrocatechol‐type inhibitor of Catechol‐O‐methyltransferase, developed for the treatment of Parkinson’s… 
2007
2007
Species‐differences in COMT inhibition by Nebicapone
Nebicapone, a new nitrocatechol‐type inhibitor of Catechol‐O‐methyltransferase, was observed to be more potent in inhibiting rat… 
2006
2006
Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)